Methods of use for antibodies that specifically bind to the EphA2 receptor

US8992912B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Veronique Blanc · Paris, FR
• Claudia Fromond · Paris, FR
• Fabienne Parker · Saint-Maur-des-Fossés, FR
• Jiawen Han · Paris, FR
• Daniel Tavares · Natick, US
• Chonghui Zhang · Brookline, US
• Min Li · New Orleans, US
• Xiao-Mai Zhou · Danbury, US
• Michel Streuli · Brookline, US

Key dates

• Filing date: Mar 6, 2013
• Grant date: Mar 31, 2015
• Expiry date: Mar 6, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/91205
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding frag…